Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment

Hepatology Research

Volumn 42, Issue 12, 2012, Pages 1157-1167

  Kozuka, Ritsuzo ^a   Enomoto, Masaru ^a   Hai, Hoang ^a   Ogawa, Tomohiro ^b   Nakaya, Mika ^a   Hagihara, Atsushi ^a   Fujii, Hideki ^a   Kobayashi, Sawako ^a   Iwai, Shuji ^a   Morikawa, Hiroyasu ^a   Tamori, Akihiro ^a   Kawada, Norifumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Core; Hepatitis C virus; Interferon; Interferon and ribavirin resistance determining region; Interferon sensitivity determining region

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMINO ACID; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MUTANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY; VIRUS GENOME; VIRUS STRAIN;

EID: 84870281856     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01046.x     Document Type: Article

References (39)

1. Izumi N, Nishiguchi S, Hino K etal. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 347-68.
2. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
4. McHutchison JG, Everson GT, Gordon SC etal. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
5. Hézode C, Forestier N, Dusheiko G etal. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
6. Kwo PY, Lawitz EJ, McCone J etal. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.
7. Enomoto M, Tamori A, Kawada N. Emerging antiviral drugs for hepatitis C virus. Rev Recent Clin Trials 2009; 4: 179-84.
8. Suzuki F, Akuta N, Suzuki Y etal. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 2009; 39: 1056-63.
9. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
10. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
11. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
13. Akuta N, Suzuki F, Hirakawa M etal. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81: 452-8.
14. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
15. Shirakawa H, Matsumoto A, Joshita S etal. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-60.
16. El-Shamy A, Sasayama M, Nagano-Fujii M etal. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pretreatment sera. Microbiol Immunol 2007; 51: 471-82.
17. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylatedinterferon/ribavirin combination therapy. Hepatology 2008; 48: 38-47.
18. Kumada H, Okanoue T, Onji M etal. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 8-13.
19. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K etal. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
20. Barbeau JM, Goforth J, Caliendo AM, Nolte FS. Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent. J Clin Microbiol 2004; 42: 3739-46.
21. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol 2010; 82: 575-82.
22. Lusida MI, Nagano-Fujii M, Nidom CA etal. Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a. J Clin Microbiol 2001; 39: 3858-64.
23. Kato N, Hijikata M, Ootsuyama Y etal. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 1990; 87: 9524-8.
24. Nishida N, Tanabe T, Takasu M etal. Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. Anal Biochem 2007; 364: 78-85.
25. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
26. Kurbanov F, Tanaka Y, Matsuura K etal. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. J Infect Dis 2010; 201: 1663-71.
27. Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsuo Y, Tazawa H. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. J Virol Methods 2007; 141: 1-6.
28. Miura M, Maekawa S, Kadokura M etal. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int 2011; 6: 386-96.
29. Rispeter K, Lu M, Zibert A, Wiese M, de Oliveira JM, Roggendorf M. The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element. J Hepatol 1998; 29: 352-61.
30. Polyak SJ, McArdle S, Liu SL etal. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998; 72: 4288-96.
31. Maekawa S, Enomoto N, Kurosaki M, Nagayama K, Marumo F, Sato C. Genetic changes in the interferon sensitivity determining region of hepatitis C virus during the natural course of chronic hepatitis C. J Med Virol 2000; 61: 303-10.
32. Nagayama K, Kurosaki M, Enomoto N etal. Time-related changes in full-length hepatitis C virus sequences and hepatitis activity. Virology 1999; 263: 244-53.
33. El-Shamy A, Shoji I, Saito T etal. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy. Microbiol Immunol 2011; 55: 418-26.
34. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76: 8505-17.
35. Lanford RE, Guerra B, Lee H etal. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003; 77: 1092-104.
36. Asahina Y, Izumi N, Enomoto N etal. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 2005; 43: 623-9.
37. Lutchman G, Danehower S, Song BC etal. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007; 132: 1757-66.
38. Hofmann WP, Polta A, Herrmann E etal. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 2007; 132: 921-30.
39. Ogawa K, Hige S, Nakanishi M etal. Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C. Antivir Ther 2009; 14: 513-22.